author-photo

Steven L. McCune

University of Alabama

15

Papers

826

Citations

Citation Trend

Filter By

Papers (15) Sort By

Journal Conference Others

Abstract LB033: Longitudinal ctDNA changes in patients with long-term response to palbociclib combination therapy for advanced breast cancer: A preliminary analysis from the real-world POLARIS study

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
315P Treatment patterns in black and indigenous people and people of color (BIPOC) receiving palbociclib for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in a real-world setting: POLARIS study results

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Standard-dose pembrolizumab (pembro) plus alternate-dose ipilimumab (ipi) in advanced melanoma: Initial analysis of KEYNOTE-029 cohort 1C.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Abstract 443: Blood-based genotyping and clinical outcomes in patients with advanced breast cancer receiving the CDK4/6 inhibitor palbociclib in real-world settings: Results from POLARIS

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
365PMeasures of functional status in adults aged ≥70 years with advanced breast cancer (ABC) receiving palbociclib (PAL) combination therapy in POLARIS

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

2019 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (438)
EP1.12-06 New Treatment Option for ES-SCLC: Patient Characteristics and Use of an Atezolizumab Regimen in the Real-World Setting

2019 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Abstract CT200: IMpower130: Progression-free survival (PFS) and safety analysis from a randomized phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab as first-line (1L) therapy in advanced non-squamous NSCLC

2019 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (1)
Hemoglobin Anti-sickling Properties Greater than Fetal A Recombinant Human Hemoglobin with Modification, and Degradation: Protein Synthesis, Post-Translation

2013
Show All
- Source
- Cite
- Save
Citations (0)
A Recombinant Human Hemoglobin with Anti-sickling Properties Greater than Fetal Hemoglobin

2004 Journal of Biological Chemistry
Show All
- Source
- Cite
- Save
Citations (55)